Stockscreener 앱 받기
3.29
6.53%
-0.23
시장 영업 전:
3.43
0.14
+4.26%
Genprex Inc 주식(GNPX)의 최신 뉴스
Genprex Stock Price Forecast. Should You Buy GNPX? - StockInvest.us
Genprex, Inc. (0A8I.IL) latest press releases and corporate news - Yahoo Finance UK
Genprex Inc. (GNPX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Genprex, Inc. (GNPX) Latest Press Releases & Corporate News - Yahoo Finance
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Genprex Selects Andelyn Biosciences to Scale Manufacturing for Diabetes Gene Therapy Program - Contract Pharma
Andelyn Biosciences Secures Manufacturing Role in Genprex Diabetes Gene Therapy Program - TipRanks
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program | Newswise - Newswise
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program - PR Newswire
Genprex Inc. (GNPX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Genprex (GNPX) Latest: Settles Near the Prior Close at $3.95 at the Close; Key Range: Support at $3.75 and Resistance at $4.15 Frame the Range in the Available RecordAD Line Divergence - dars.gov.et
Genprex signs CDMO deal to scale up diabetes gene therapy manufacturing - Minichart
Form 8K Genprex Inc For: 18 August By Investing.com - Investing.com Nigeria
Genprex partners with CDMO for diabetes gene therapy manufacturing By Investing.com - Investing.com Nigeria
Genprex (GNPX) Partners with CDMO to Advance Diabetes Gene Thera - GuruFocus
Genprex partners with CDMO for diabetes gene therapy manufacturing - Investing.com
GenprexTransfers Diabetes Product Manufact - Moomoo
Genprex advances AAV diabetes gene therapy manufacturing - TipRanks
Genpre announces CDMO partnership to scale AAV diabetes gene therapy toward cGMP clinical supply - TradingView
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy - PR Newswire
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Posts $0.64 Per Share Loss as Pipeline Development ContinuesGuidance Update - vinanet.vn
Genprex, Inc. Q2 2026: Net loss $(4.45M), EPS $(9.40) — 10-Q Summary - TradingView
Genprex (NASDAQ: GNPX) details Q2 loss and cash runway into 2027 - Stock Titan
Genprex, Inc. (GNPX) Debt 2025 - Stock Titan
Genprex (GNPX) Surges 5% on Renewed Biotech Interest — Key Levels to WatchShort Setup Alerts - vinanet.vn
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer (PR Newswire) - Aktiellt
Genprex Inc (STU:2DE1) Stock Earnings Transcripts - GuruFocus
Genprex Inc (STU:2DE1) Stock Price & 30 Year Financial Data - GuruFocus
Genprex Inc (GNPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genprex Inc (GNPX) Stock News Today - TradingKey
Genprex (GNPX) Q1 2026 Earnings: Net Loss of $0.64 Per Share Highlights Pre-Revenue Clinical Development StagePretax Income Report - careplusvn.com
Genprex Regains Nasdaq Compliance, Listing Status Secured - The Globe and Mail
Genprex, Inc. (NASDAQ: GNPX) regains Nasdaq minimum bid compliance - Stock Titan
Genprex partners with Roche Diagnostics on biomarker validation for NSCLC - Yahoo Finance
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies - Morningstar
Genprex, Roche Partner on NSCLC Biomarker Validation - TipRanks
Genprex Shares Rise After Collaboration With Roche Diagnostics - finance.yahoo.com
GNPX Stock Draws Trader Focus After Wild Price Swing - StocksToTrade
Why is Genprex stock sliding today? By Investing.com - Investing.com Canada
Weekly Recap: Nasdaq exception and Roche Diagnostics TROP2 validation - TradingView
Genprex stock rises on Roche Diagnostics collaboration - Investing.com India
Genprex stock rises on Roche Diagnostics collaboration By Investing.com - Investing.com Nigeria
Genprex partners with Roche on lung cancer biomarker studies - Investing.com Nigeria
Genprex partners with Roche on lung cancer biomarker studies By Investing.com - Investing.com Canada
Lung Cancer Gene Therapy Takes First Step Toward AI Biomarker Selection - techtimes.com
Genprex Granted Nasdaq Listing Exception Amid Compliance Push - The Globe and Mail
Genprex Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Genprex Inc (GNPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genprex Inc (GNPX) Institutional Confidence - TradingKey
Genprex Inc (GNPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genprex Inc (GNPX) Earnings Date & Reports & Earnings News - TradingKey
Genprex Inc (GNPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genprex Inc (GNPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GNPX|Genprex Inc|Price:3.380|Chg%:-0.370 - TradingKey
TradingKey - TradingKey
GNPX|Genprex Inc|Price:7.735|Chg%:-0.075 - TradingKey
GNPX|Genprex Inc|Price:4.700|Chg%:+0.230 - TradingKey
Genprex Inc Revenue Breakdown – LSE:0A8I - TradingView
3.06%
2.55%
자본화:
|
볼륨(24시간):